Web
Site
Search
Personpolitik for region Hovedstad
Personal data
Privacy policy
Vacancies
Login
About us
About
Organisation
Staff
Contact Us
Press Office
Om CHIP (Danish)
Links
Annual Reports
Privacy Policy
Research
Studies
RESPOND
About
Meetings
2021
2020
2019
2018
Study documents
Study Group
Scientific Interest Groups
Hepatitis
Outcomes with ARVs
Tuberculosis
Public Health
PrEPaRe
Patient questionaire
ESTIHIV - HIV Estimation Tool
Submit Research Proposal
Publications
2021
2020
Presentations
2020
2019
Newsletters
Contact
Collaborating cohorts and partners
AHIVCOS
AHOD
ATHENA
CHU Saint-Pierre
University Hospital Cologne
University Hospital Bonn
EuroSIDA
Frankfurt HIV Cohort Study
Georgian National AIDS Health Information System
ICONA
Modena HIV Cohort
Nice HIV Cohort
PISCIS
SHCS
Swedish InfCare HIV Cohort
Royal Free HIV Cohort Study
San Raffaele Scientific Institute
EuroSIDA
About
Newsletters
2017
2016
2015
2014
2013
2012
2011
Sample shipment
Order shipment
Study documents
Study group
Contacts
RESPOND
Submit research concept
Publications
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2006-2011
1997-2005
AIDS in Europe
Tracking HIV/AIDS
EuroSIDA a multicenter study, 1994-2009
Presentations
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
MISTRAL
CARE
Study Documents
ENFORCE
About ENFORCE
Study Governance
Study Documents
Info til deltagere
START
About
Data Protection
Completed Substudies
Informed Consent
Monitoring
Genomics
Neurology
Arterial Elasticity
Pulmonary
Bone Mineral Density
Liver Fibrosis Progression
Study group
ICC Newsletter
Presentations
Publications
2021
2020
2019
2018
2017
2016
2015
COVID-19 Studies
ACTT Study
Publications
ICOS Study
TICO Study
Publications
Influenza Studies
Data Protection
FLU 003 Plus
FLU-IVIG
Genomics
INTEGRATE JA
TB:HIV
About
TB:HIV Study Group
Data Collection
Documents
Newsletters
Presentations
Publications
Submit research concept
D:A:D
About
Meetings
Newsletters
Position Statement
Presentations
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
Publications
2020
2019
2018
2017
2016
2015
2014
2003-2013
Study Documents
Study Group
Submit research concept
Completed Studies
The ESPRIT Trial
About IL-2
Publications
Study Group
The SILCAAT trial
Publications
Study Group
PASS
Publications
STALWART
About
Newsletters
Publications
NEAT001
Ancillary & Substudies
Adherence
Bone
Neurocognitive Function
Pharmacoeconomics
Pharmacogenetics
Quality of Life
Renal Function
Viral/Immunologic Dynamics/Inflammation
Viral Subtype
Study Group
Publications
Presentations
The SMART study
About
Map
Presentations
Publications
Study Group
PARTNER
PARTNER 2
Meetings
Conferences
Teleconferences
Newsletters
Participating Sites
Austria
Belgium
Denmark
Finland
France
Germany
Ireland
Italy
Portugal
Spain
Sweden
Switzerland
The Netherlands
UK
Press
Articles and Interviews
Links to media coverage
Recruitment Strategies
Study Documents
General
Danish
Dutch
English
Finnish
Flemish
French
German
Swiss version
Italian
Swiss version
Portuguese
Spanish
Swedish
Informed Consent Forms
Study Group
Publications
Q and A
Final results
Q and A 2018
About
PARTNER press release 2018
Optimizing HIV and HBV-HCV testing in primary care
About
Who to Test
Test af HIV i almen praksis
Testning og tolkning af resultater
Test af HBV og HCV i almen praksis
CASS
Protocol
ProbeC
HIDES
COHERE
FLU 002 Plus
EuroCoord
HA-REACT
C. diff
Publications
Clinical
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2006-2011
2000-2005
Public Health
2020
2019
2018
2017
2016
2015
2014
2013
Reports
2016
2015
2014
2013
2012
Dissertations
Presentations
2020
2019
2018
2017
2016
2015
2014
2013
2012
2006-2011
2000-2005
PERSIMUNE
Clinical programs
MATCH
Publications
Presentations 2015
Presentations 2014
Vaccine recommendations MATCH
CLASS
SACC
Booklets on hepatitis C
SACC in media
CATCH
Resources
Clinical risk scores
Tools & Standards
CoDe
About
Pilot
Working Group
Documents
CoDe Status
Presentations
Publications
Review
Reviewer FAQ
Methodology
Technical
CoDe Reviewers
HICDEP
Acknowledgements
Documents
Files
Education
EACS online course
IATA training
Infektionsmedicin (KU)
Collaborations
INSIGHT
INSIGHT Network
Newsletters
Publications
Presentations
WHO CC
About
Activities
Publications
Guidelines development
Country missions
Online course
Contact
EuroTEST
OptTEST
Resources
Clinical risk scores
Welcome to the Risk Assesment Tool System (RATS). Please select the desired values from the list below.
General
Cardiovascular
Kidney
EuroSida AIDS/Death risk score
The EuroSida risk score algorithm is used to calculate a given individuals risk of new AIDS or death occuring within the next 3, 6 and 12 months. Required information: Gender, age, weight, height, CD4 measurements, infected via IDU, AIDS at start of cART, ART experience, ART status, HIV viral load & haemoglobin.
2007 Sep - Mocroft A et al.
Abstract
FENCE score
The FENCE score estimates the risk of developing febrile neutropenia in the first cycle of chemotherapy in treatment-naïve patients with solid cancers or diffuse large b-cell lymphoma treated with standard first-line chemotherapy. Required information: Cycle length, age, gender, planned length of the first cycle, cancer type, disease stage, albumin, bilirubin, eGFR, CRP, infection before chemotherapy, number of and types of chemotherapy drugs.
2018 – Aagaard T et al.
Abstract
CSR
FENCE Score
The
CSR
FENCE score estimates the risk of developing febrile neutropenia in any of the cycles 2-6 of standard first-line chemotherapy in patients with solid cancers. Required information: Cycle length, FENCE risk group, types of chemotherapy drugs, radiotherapy, cycle number, FN or neutropenia in previous cycles, G-CSF prophylaxis.
2019 – Aagaard T et al.
Abstract
D:A:D (R) CVD 5 and 10 year risk score
The D:A:D (R) CVD prediction tool/algorithm is based on a reduced model, and estimates the risk of an individual developing a cardiovascular disease (CVD) within the next 5 and 10 years. The D:A:D (R) does not include ART as parameters, an can be used in settings where this information is not readily available. Required information: Gender, age, smoking status, diabetes (diagnosis or on antidiabetic treatment), family CVD history, systolic BP, total cholesterol, HDL, and CD4-count. The composite CVD outcome includes: Myocardial infarction, stroke, invasive coronary artery procedure (including coronary artery by-pass or angioplasty and carotid artery endarterectomy) or death from coronary heart disease. Constraint: The D:A:D (R) model is valid for HIV infected individuals aged 18-75 years.
2016 Jan - Friis-Møller N et al.
Abstract
D:A:D (F) CVD 5 and 10 year risk score
The D:A:D (F) CVD prediction tool/algorithm is based on a full model, and estimates the risk of an inividual developing a cardiovascular disease (CVD) within the next 5 and 10 years. Required information: Gender, age, smoking status, diabetes (diagnosis or on antidiabetic treatment), family CVD history, systolic BP, total cholesterol, HDL, CD4, cumulative PI exposure, cumulative NRTI exposure & current abacavir use. The composite CVD outcome includes: Myocardial infarction, stroke, invasive coronary artery procedure (including coronary artery by-pass or angioplasty and carotid artery endarterectomy) or death from coronary heart disease. Constraint: The D:A:D (F) model is valid for HIV infected individuals aged 18-75 years, with cumulative NRTI exposure up to about 8-10 years, and PI exposure up to around 5-6 years. Extrapolating beyond these exposures without recalibrating will lead to over estimates of CVD risk. For individuals who are highly exposed to ART, use of the D:A:D (R) model is recommended.
2016 Jan - Friis-Møller N et al.
Abstract
Framingham CVD 5 and 10 year risk score
The Framingham algorithm estimates the risk of developing a cardiovascular disease within the next 5 years (modified to be compared with the D:A:D CVD 5 year risk score) and next 10 years (original Framingham risk score). The Framingham model is valid for individuals aged 30 to 75. Required information: Gender, age, smoking status, diabetes (diagnosis or on antidiabetic treatment), systolic BP, antihypertensive treatment, total cholesterol, HDL
2016 Jan - Friis-Møller N et al.
Abstract
2008 Feb, D'Agostino RB Sr et al.
Abstract
MI Number needed to harm
Number needed to harm estimates the risk of a myocardial infarction appearing in HIV-1-positive individual treated with abacavir within 5 or 10 years. Required information: Gender, age, smoking status, diabetes, LVH visible on ECG, systolic BP, cholesterol, HDL & personal CVD history.
2010 Mar - Kowalska JD et al.
Abstract
Estimated glomerular filtration rate
This algorithm calculates the estimated glomerular filtration using MDRD (Modification of Diet in Renal Disease Study Group). Required information: Gender, age, ethnicity, plasma creatinine, urea nitrogen and albumin
1999 Mar - Levey AS et al.
Abstract
Short chronic kidney disease risk score
The short chronic kidney disease algorithm calculates the possibility of an individual developing CKD within the next five years. The short version of this algorithm disregards smoking status, hypertension, diabetes, and prior CVD. Required information: Age, gender, GFR, IDU as HIV-risk group, HCV, & nadir CD4.
If this is selected in combination with the estimated glomerular filtration rate algorithm, it will be used to calculate the GFR needed by this algorithm.
2015 Mar - Mocroft A et al.
Abstract
Full chronic kidney disease risk score
The full chronic kidney disease algorithm calculates the possibility of developing CKD within the next five years. Required information: Age, gender, IDU as HIV-risk group, HCV, nadir CD4, hypertension history, personal CVD history & diabetes.
If this is selected in combination with the estimated glomerular filtration rate algorithm, it will be used to calculate the GFR needed by this algorithm.
2015 Mar - Mocroft A et al.
Abstract
This site uses cookies
We use cookies to analyze our traffic and provide a better user experience. You give your consent by clicking on the OK button or choose to continue.
Read more about our privacy and cookie policy